Document is current
Any future updates will be listed below
-
Authors
Evans, D. Gareth http://orcid.org/0000-0002-8482-5784
Mostaccioli, Stefania
Pang, David
Fadzil O Connor, Mary
Pittara, Melpo
Champollion, Nicolas
Wolkenstein, Pierre
Thomas, Nick
Ferner, Rosalie E.
Kalamarides, Michel
Peyre, Matthieu
Papi, Laura
Legius, Eric
Becerra, Juan Luis
King, Andrew http://orcid.org/0000-0002-6546-7248
Duff, Chris
Stivaros, Stavros http://orcid.org/0000-0003-3023-541X
Blanco, Ignacio http://orcid.org/0000-0002-7414-7481
-
Funding
Funding for this research was provided by:
DH | NIHR | Health Services Research Programme (1215-200074)
- License Information
-
More Information
Article History
Received: 7 November 2021
Revised: 4 February 2022
Accepted: 7 March 2022
First Online: 1 April 2022
Competing interests
: All authors of the ERN GENTURIS guideline have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a competing interests. DGE and RF report receipt of honoraria or consultation fees from AstraZeneca. MK and DGE report receipt of honoraria or consultation fees from Recursion. DGE and EL report receipt of honoraria or consultation fees from Springworks Therapeutics. LP reported receipt of grants/research support from Devyser. NT reports participation in a company sponsored speaker’s bureau from Stryker. DP reports reimbursement of travel expenses for medical conferences by Medtronic and Nevro Corp. All participants of the ERN GENTURIS schwannomatosis Delphi survey have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a competing interests. HH report receipt of honoraria or consultation fees from Pfizer. BF reports receipt of honoraria from Gruenenthal UK and Gruenenthal Europe.
